RIPK3 and cancer: Finally, the role of the balance between RIPK1 and RIPK3 in inducing cell death in cancer cells has recently been highlighted by the study using Protac targeting RIPK1, which was able to induce cell death in cancer cells (Mannion et al, 2024).